Elon's Vision
  • Contacts
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Elon's Vision
No Result
View All Result
Home Stock

Oxford Medical Products Confirms Positive Trial Results for Sirona Weight-Loss Technology

by
October 29, 2024
in Stock
0
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Oxford Medical Products is excited to announce successful topline outcomes from the initial randomised controlled trial (RCT) of Sirona, a novel, non-invasive, non-pharmaceutical technology designed to aid weight loss. In a 12-week RCT, Sirona exhibited a good safety profile, was well-tolerated, and demonstrated clear efficacy, with participants in the Sirona group achieving greater weight loss…

Source

Previous Post

Gradely Rolls Out Customised Tutoring to Help UK Students Excel in GCSEs, SATs, and 11+ Exams

Next Post

BBC Radio 4 Appeal to Highlight DSM Foundation, a Non-Profit Focused on Drug Education

Next Post

BBC Radio 4 Appeal to Highlight DSM Foundation, a Non-Profit Focused on Drug Education

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest

Jay Bhattacharya on Public Health

October 12, 2021

Microsoft Planner vs Trello: Which Project Management Tool is Better?

May 24, 2023

That Bangladesh Mask Study!

December 1, 2021

Antitrust Regulation Assumes Bureaucrats Know the “Correct” Amount of Competition

November 24, 2021
Bank of England faces knife-edge decision on rate cut as inflation eases but growth risks mount

Bank of England faces knife-edge decision on rate cut as inflation eases but growth risks mount

0

0

0

0
Bank of England faces knife-edge decision on rate cut as inflation eases but growth risks mount

Bank of England faces knife-edge decision on rate cut as inflation eases but growth risks mount

October 31, 2025
Twice-Yearly Time Travel Is Bad for Your Health

Twice-Yearly Time Travel Is Bad for Your Health

October 31, 2025
Leon co-founder set to reclaim the chain from Asda for a fraction of its 2021 sale price

Leon co-founder set to reclaim the chain from Asda for a fraction of its 2021 sale price

October 31, 2025
Podcast: Obamacare & the Government “Shutdown”

Podcast: Obamacare & the Government “Shutdown”

October 31, 2025

Recent News

Bank of England faces knife-edge decision on rate cut as inflation eases but growth risks mount

Bank of England faces knife-edge decision on rate cut as inflation eases but growth risks mount

October 31, 2025
Twice-Yearly Time Travel Is Bad for Your Health

Twice-Yearly Time Travel Is Bad for Your Health

October 31, 2025
Leon co-founder set to reclaim the chain from Asda for a fraction of its 2021 sale price

Leon co-founder set to reclaim the chain from Asda for a fraction of its 2021 sale price

October 31, 2025
Podcast: Obamacare & the Government “Shutdown”

Podcast: Obamacare & the Government “Shutdown”

October 31, 2025

Disclaimer: ElonsVision.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • Contacts
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 ElonsVision. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 ElonsVision. All Rights Reserved.